Activation of IGF1R/p110β/AKT/mTOR Confers Resistance to Α-Specific PI3K Inhibition

Cedric Leroy,Pedro Ramos,Karen Cornille,Debora Bonenfant,Christine Fritsch,Hans Voshol,Mohamed Bentires-Alj

Breast cancer research（2016）

引用 64|浏览42

暂无评分

摘要

The PI3K pathway is hyperactivated in many cancers, including 70 % of breast cancers. Pan- and isoform-specific inhibitors of the PI3K pathway are currently being evaluated in clinical trials. However, the clinical responses to PI3K inhibitors when used as single agents are not as efficient as expected.

查看译文

关键词

Phosphatidylinositol 3-kinase,p110α,p110β,Resistance,Breast cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要